Moderna has secured FDA approval for its respiratory syncytial virus (RSV) vaccine, giving it a chance to generate revenue from a second product as sales of its Spikevax COVID-19 shot have slumped.

Graeme Sloan / Bloomberg via Getty Images Novavax said the Food and Drug Administration allowed it to continue testing a combination COVID-19-flu and standalone flu vaccine that had been put on hold.

Moderna, Inc.'s stock plummets as challenges mount, including vaccine skepticism, competitive pressures, and the RFK ...

Days after Pfizer and BioNTech reported surprisingly strong sales of their updated COVID-19 vaccines, Moderna has done the same. The Massachusetts-based company said that third-quarter revenue ...

Moderna said Thursday its newest Covid vaccine saw benefits after winning approval in the U.S. three ... over the next three years. FTC sues drug middlemen for allegedly inflating insulin ...

Moderna reported $1.8 billion in Spikevax ... U.S. market following the earlier launch of the updated COVID-19 vaccine. With FDA approval granted three weeks earlier than in the previous year ...

Valneva has submitted an application to the U.S. FDA to ... chikungunya vaccine, IXCHIQ®, to adolescents and highlight its long-term antibody persistence. The vaccine, already approved for ...

Moderna said it is still on track to file for approval this ... generation COVID vaccine. The company said it planned to use priority review vouchers to speed up the FDA applications for its ...

Moderna’s top executives have sought to reassure investors they will be able to carry out the comeback plans announced in ...

Moderna said on Friday Canada's health regulator has approved its vaccine for respiratory syncytial virus, or RSV, in adults 60 years and older, making it the country's first authorized mRNA-based ...

said the Drug Control Authority (DCA) agreed to give conditional approval to Spikevax, or what is commonly known as the Moderna Covid-19 vaccine.

mRESVIA is Moderna's second approved product in Canada, the first mRNA vaccine against RSV, and the only one in single-dose pre-filled syringes Canada is the fourth jurisdiction to approve mRESVIA ...